Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

European Journal of Medical Genetics

Volumn 54, Issue 1, 2011, Pages 14-18

  Motaghedi, Roja ^a   Lipman, Elizabeth G ^a   Hogg, Jeannette E ^a   Christos, Paul J ^a   Vogiatzi, Maria G ^a   Angulo, Moris A ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

CB1 cannabinoid receptor; Obesity; Prader Willi syndrome; Rimonabant

Indexed keywords

GHRELIN; LEPTIN; METFORMIN; PLACEBO; RIMONABANT; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ADULT; ANTHROPOMETRY; ANXIETY DISORDER; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; DYSTHYMIA; FEMALE; HORMONE RELEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PARANOIA; PRADER WILLI SYNDROME; PSYCHOSIS; SLEEP DISORDER;

ADIPOSE TISSUE; ADOLESCENT; ADULT; BODY WEIGHT; DOUBLE-BLIND METHOD; FASTING; FEMALE; GHRELIN; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; MALE; PARANOID DISORDERS; PILOT PROJECTS; PIPERIDINES; PRADER-WILLI SYNDROME; PSYCHOTIC DISORDERS; PYRAZOLES; RADIOIMMUNOASSAY; RECEPTORS, CANNABINOID; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951941782     PISSN: 17697212     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejmg.2010.09.015     Document Type: Article

References (37)

1. Benowitz N.L., Jones R.T., Lerner C.B. Depression of growth hormone and cortisol response to insulin-induced hypoglycemia after prolonged oral delta-9-tetrahydrocannabinol administration in man. J. Clin. Endocrinol. Metab. 1976, 42:938-941.
2. Bensaid M., Gary-Bobo M., Esclangon A., Maffrand J.P., Le Fur G., Oury-Donat F., Soubrie P. The cannabinoid cb1 receptor antagonist sr141716 increases acrp30 mrna expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 2003, 63:908-914.
3. Bouhours-Nouet N., Gatelais F., Boux de Casson F., Rouleau S., Coutant R. The insulin-like growth factor-i response to growth hormone is increased in prepubertal children with obesity and tall stature. J. Clin. Endocrinol. Metab. 2007, 92:629-635.
4. Butler M.G., Bittel D.C., Talebizadeh Z. Plasma peptide yy and ghrelin levels in infants and children with prader-willi syndrome. J. Pediatr. Endocrinol. Metab. 2004, 17:1177-1184.
5. Cani P.D., Montoya M.L., Neyrinck A.M., Delzenne N.M., Lambert D.M. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, sr141716a (rimonabant) and oleoylethanolamide. Br. J. Nutr. 2004, 92:757-761.
6. Corrias A., Bellone J., Beccaria L., Bosio L., Trifiro G., Livieri C., Ragusa L., Salvatoni A., Andreo M., Ciampalini P., Tonini G., Crino A. Gh/igf-i axis in prader-willi syndrome: evaluation of igf-i levels and of the somatotroph responsiveness to various provocative stimuli. Genetic obesity study group of italian society of pediatric endocrinology and diabetology. J. Endocrinol. Invest. 2000, 23:84-89.
7. Cummings D.E., Clement K., Purnell J.Q., Vaisse C., Foster K.E., Frayo R.S., Schwartz M.W., Basdevant A., Weigle D.S. Elevated plasma ghrelin levels in prader willi syndrome. Nat. Med. 2002, 8:643-644.
8. DelParigi A., Tschop M., Heiman M.L., Salbe A.D., Vozarova B., Sell S.M., Bunt J.C., Tataranni P.A. High circulating ghrelin: a potential cause for hyperphagia and obesity in prader-willi syndrome. J. Clin. Endocrinol. Metab. 2002, 87:5461-5464.
9. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410:822-825.
10. Dykens E., Shah B. Psychiatric disorders in prader-willi syndrome: epidemiology and management. CNS Drugs 2003, 17:167-178.
11. Feigerlova E., Diene G., Conte-Auriol F., Molinas C., Gennero I., Salles J.P., Arnaud C., Tauber M. Hyperghrelinemia precedes obesity in prader-willi syndrome. J. Clin. Endocrinol. Metab. 2008, 93:2800-2805.
12. Goldstone A.P., Brynes A.E., Thomas E.L., Bell J.D., Frost G., Holland A., Ghatei M.A., Bloom S.R. Resting metabolic rate, plasma leptin concentrations, leptin receptor expression, and adipose tissue measured by whole-body magnetic resonance imaging in women with prader-willi syndrome. Am. J. Clin. Nutr. 2002, 75:468-475.
13. Goldstone A.P., Holland A.J., Hauffa B.P., Hokken-Koelega A.C., Tauber M. Recommendations for the diagnosis and management of prader-willi syndrome. J. Clin. Endocrinol. Metab. 2008, 93:4183-4197.
14. Gunay-Aygun M., Schwartz S., Heeger S., O'Riordan M.A., Cassidy S.B. The changing purpose of prader-willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 2001, 108:E92.
15. Haqq A.M., Grambow S.C., Muehlbauer M., Newgard C.B., Svetkey L.P., Carrel A.L., Yanovski J.A., Purnell J.Q., Freemark M. Ghrelin concentrations in prader-willi syndrome (pws) infants and children: changes during development. Clin. Endocrinol. 2008, 69:911-920.
16. Holm V.A., Cassidy S.B., Butler M.G., Hanchett J.M., Greenswag L.R., Whitman B.Y., Greenberg F. Prader-willi syndrome: consensus diagnostic criteria. Pediatrics 1993, 91:398-402.
17. T. Kelesidis, I. Kelesidis, S. Chou, C.S. Mantzoros, Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann. Intern. Med. 2010;152:93-100.
18. Laurance B.M., Brito A., Wilkinson J. Prader-willi syndrome after age 15 years. Arch. Dis. Child. 1981, 56:181-186.
19. Ledbetter D.H., Riccardi V.M., Airhart S.D., Strobel R.J., Keenan B.S., Crawford J.D. Deletions of chromosome 15 as a cause of the prader-willi syndrome. N. Engl. J. Med. 1981, 304:325-329.
20. Liu Y.L., Connoley I.P., Wilson C.A., Stock M.J. Effects of the cannabinoid cb1 receptor antagonist sr141716 on oxygen consumption and soleus muscle glucose uptake in lep(ob)/lep(ob) mice. Int. J. Obes. (Lond). 2005, 29:183-187.
21. Loche S., Cappa M., Borrelli P., Faedda A., Crino A., Cella S.G., Corda R., Muller E.E., Pintor C. Reduced growth hormone response to growth hormone-releasing hormone in children with simple obesity: evidence for somatomedin-c mediated inhibition. Clin. Endocrinol. 1987, 27:145-153.
22. Miller J.L., Goldstone A.P., Couch J.A., Shuster J., He G., Driscoll D.J., Liu Y., Schmalfuss I.M. Pituitary abnormalities in prader-willi syndrome and early onset morbid obesity. Am. J. Med. Genet. A. 2008, 146A:570-577.
23. Nakazato M., Murakami N., Date Y., Kojima M., Matsuo H., Kangawa K., Matsukura S. A role for ghrelin in the central regulation of feeding. Nature 2001, 409:194-198.
24. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Batkai S., Harvey-White J., Mackie K., Offertaler L., Wang L., Kunos G. Endocannabinoid activation at hepatic cb1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 2005, 115:1298-1305.
25. Osei-Hyiaman D., Liu J., Zhou L., Godlewski G., Harvey-White J., Jeong W.I., Batkai S., Marsicano G., Lutz B., Buettner C., Kunos G. Hepatic cb1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J. Clin. Invest. 2008, 118:3160-3169.
26. Pagotto U., Marsicano G., Fezza F., Theodoropoulou M., Grubler Y., Stalla J., Arzberger T., Milone A., Losa M., Di Marzo V., Lutz B., Stalla G.K. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J. Clin. Endocrinol. Metab. 2001, 86:2687-2696.
27. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: rio-north america: a randomized controlled trial. J. Am. Med. Assoc. 2006, 295:761-775.
28. Pietrobelli A., Allison D.B., Faith M.S., Beccaria L., Bosio L., Chiumello G., Campfield L.A., Heymsfield S.B. Prader-willi syndrome: relationship of adiposity to plasma leptin levels. Obes. Res. 1998, 6:196-201.
29. Proto C., Romualdi D., Cento R.M., Romano C., Campagna G., Lanzone A. Free and total leptin serum levels and soluble leptin receptors levels in two models of genetic obesity: the prader-willi and the down syndromes. Metabolism 2007, 56:1076-1080.
30. Ravinet Trillou C., Delgorge C., Menet C., Arnone M., Soubrie P. Cb1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 2004, 28:640-648.
31. Rettori V., Wenger T., Snyder G., Dalterio S., McCann S.M. Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat. Neuroendocrinology 1988, 47:498-503.
32. Russell H., Oliver C. The assessment of food-related problems in individuals with prader-willi syndrome. Br. J. Clin. Psychol./Br. Psychol. Soc. 2003, 42:379-392.
33. Soni S., Whittington J., Holland A.J., Webb T., Maina E., Boer H., Clarke D. The course and outcome of psychiatric illness in people with prader-willi syndrome: implications for management and treatment. J. Intellect. Disabil. Res. 2007, 51:32-42.
34. Swaab D.F. Prader-willi syndrome and the hypothalamus. Acta Paediatr. Suppl. 1997, 423:50-54.
35. US Food and Drug Administration EaMDAC: Fda briefing document: Zimulti (rimonabant) tablets, 20 mg. Rockville, 2007, 2010.
36. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the rio-europe study. Lancet 2005, 365:1389-1397.
37. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67:361-370.